Mounjaro UK: Complete Patient Guide

Mounjaro is the brand name for tirzepatide, a medication manufactured by Eli Lilly that works through a novel dual-action mechanism. Unlike earlier GLP-1 receptor agonists (such as semaglutide), tirzepatide activates two incretin hormone receptors simultaneously: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1).

How the dual mechanism works:

• •GLP-1 receptor activation: Slows gastric emptying, reduces appetite, enhances insulin secretion in response to food, and suppresses glucagon release. This is the same mechanism used by semaglutide (Ozempic/Wegovy)
• •GIP receptor activation: Enhances insulin sensitivity, may improve fat metabolism, and appears to have complementary effects on appetite regulation and energy expenditure. The GIP component is what distinguishes tirzepatide from pure GLP-1 agonists

The dual agonism creates a synergistic effect — the combination appears to produce greater metabolic benefits than either pathway activated alone. This is reflected in clinical trial data showing superior weight loss and glycaemic control compared to semaglutide in head-to-head studies.

Administration:

Mounjaro is administered as a once-weekly subcutaneous injection using a pre-filled pen device. The pens are designed for self-administration and come with built-in needles, making the injection process straightforward for most patients.

Mounjaro was originally developed and licensed for type 2 diabetes management. In November 2023, the MHRA approved tirzepatide (under the brand name Mounjaro) for weight management in the UK, and NICE subsequently published guidance on its use.

Access to Mounjaro in the UK depends on whether you are seeking it for type 2 diabetes or for weight management, and whether you pursue NHS or private routes.

NHS access for type 2 diabetes:

Mounjaro is available on the NHS for adults with type 2 diabetes who meet specific criteria, typically when other medications (metformin, sulfonylureas, SGLT2 inhibitors) have not achieved adequate glycaemic control. Your GP or diabetes specialist can prescribe it as part of your diabetes management plan. NICE technology appraisal guidance supports its use in this context.

NHS access for weight management:

NHS access for weight management is more restricted and follows a tiered pathway:

• •Tier 3 specialist weight management services: Mounjaro may be prescribed through specialist weight management services for patients with a BMI of 35+ (or 30+ with weight-related comorbidities). However, not all Tier 3 services currently include tirzepatide in their formulary
• •Waiting lists: NHS Tier 3 services often have substantial waiting lists, and availability of specific medications varies by region and local commissioning decisions
• •NICE guidance: NICE has appraised tirzepatide for weight management in adults with a BMI of 35+ (or 30+ with at least one weight-related comorbidity), subject to specific clinical criteria

Private access:

Private access is more straightforward but comes at a cost:

• •Private clinics: Many private weight management and metabolic health clinics now prescribe Mounjaro following a consultation and appropriate assessment
• •Online prescribing services: Several regulated online platforms offer Mounjaro prescriptions after a remote consultation (ensure any platform is CQC registered and uses GMC-registered prescribers)
• •Private GP: Some private GPs will prescribe Mounjaro for weight management

Cost comparison:

• •NHS: Standard prescription charge (£9.90 per item in England, free in Scotland, Wales, and Northern Ireland)
• •Private: Approximately £150–£250 per month depending on the dose and supplier, plus consultation fees

The evidence base for Mounjaro's effectiveness in weight management comes primarily from the SURMOUNT clinical trial programme — a series of large, well-designed studies that established tirzepatide as the most effective anti-obesity medication to date.

SURMOUNT-1 (2022):

• •2,539 adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related comorbidity
• •Participants did not have type 2 diabetes
• •72-week treatment duration
• •Results by dose:
• • - 5mg: 15.0% mean weight loss
• • - 10mg: 19.5% mean weight loss
• • - 15mg: 20.9% mean weight loss
• • - Placebo: 3.1% weight loss
• •Over 50% of participants on the 15mg dose lost more than 20% of their body weight — a result previously achievable only with bariatric surgery

SURMOUNT-2 (2023):

• •938 adults with type 2 diabetes and obesity/overweight
• •72-week treatment duration
• •Results: 12.8% (10mg) and 14.7% (15mg) mean weight loss, with significant improvements in HbA1c
• •Demonstrated that tirzepatide produces meaningful weight loss even in the more "weight-loss-resistant" diabetic population

SURMOUNT-3 and SURMOUNT-4:

• •SURMOUNT-3 examined tirzepatide following an initial intensive lifestyle intervention (diet and exercise), showing additional weight loss beyond what lifestyle changes alone achieved
• •SURMOUNT-4 studied the effects of treatment withdrawal, demonstrating that most weight was regained after discontinuation — underscoring that ongoing treatment is needed to maintain results

How these results compare:

• •Semaglutide 2.4mg (Wegovy): STEP trials showed 15–17% mean weight loss at 68 weeks
• •Tirzepatide 15mg (Mounjaro): SURMOUNT-1 showed 20.9% mean weight loss at 72 weeks
• •Liraglutide 3mg (Saxenda): SCALE trials showed approximately 8% mean weight loss

Tirzepatide's superior efficacy is attributed to its dual GIP/GLP-1 mechanism, which appears to provide additional metabolic benefits beyond GLP-1 agonism alone.

Mounjaro uses a structured dose escalation protocol designed to minimise gastrointestinal side effects while gradually building to the therapeutic dose. Understanding this process helps set realistic expectations about timing and results.

The standard dose escalation schedule:

| Dose | Duration | Purpose | |------|----------|---------| | 2.5mg | Weeks 1–4 | Starting dose — primarily for tolerability, minimal weight loss expected | | 5mg | Weeks 5–8 | First therapeutic dose — appetite suppression begins, early weight loss | | 7.5mg | Weeks 9–12 | Intermediate dose — increasing efficacy | | 10mg | Weeks 13–16 | Higher therapeutic dose — significant appetite suppression | | 12.5mg | Weeks 17–20 | Intermediate step to maximum dose | | 15mg | Week 21 onwards | Maximum dose — strongest appetite suppression and metabolic effects |

Important notes about dose escalation:

• •Each dose step lasts a minimum of 4 weeks: This allows your body to adjust and helps manage GI side effects. Some prescribers may recommend longer at each step if side effects are problematic
• •Not everyone reaches 15mg: The goal is to find the dose that provides adequate clinical benefit with acceptable side effects. Some patients achieve their targets at 5mg or 10mg
• •Dose adjustments are flexible: If side effects are significant at a particular dose, your prescriber may keep you at the current dose for longer before escalating, or may not escalate further
• •The 2.5mg dose is not therapeutic: It is purely a tolerability/initiation dose. Do not be discouraged if you see minimal weight loss during the first month

What to expect at each stage:

• •Weeks 1–4 (2.5mg): Mild appetite changes, possible mild nausea. Weight loss typically 0–1kg
• •Weeks 5–12 (5–7.5mg): Noticeable appetite suppression, reduced portion sizes, possible nausea and GI symptoms. Weight loss accelerates
• •Weeks 13–20 (10–12.5mg): Strong appetite suppression, significant dietary behaviour changes. Most GI side effects begin to settle
• •Week 21+ (15mg): Maximum appetite suppression. Weight loss continues at a steady rate, typically 0.5–1kg per week

Practical tips:

• •Take your injection on the same day each week at approximately the same time
• •Eat smaller, more frequent meals rather than large portions — this significantly reduces nausea
• •Stay well hydrated
• •Report persistent or severe side effects to your prescriber rather than pushing through

Like all medications, Mounjaro has side effects. The majority are gastrointestinal and tend to be most pronounced during dose escalation, settling as your body adjusts.

Very common side effects (affecting more than 1 in 10 patients):

• •Nausea: The most frequently reported side effect. Typically worst during the first 2–4 weeks at each new dose and then improves. Affects approximately 25–30% of patients
• •Diarrhoea: Affects approximately 15–20% of patients, usually mild to moderate and self-limiting
• •Reduced appetite: This is technically the intended effect, but some patients find the degree of appetite suppression uncomfortable initially
• •Constipation: Affects approximately 10–15% of patients, often manageable with increased fibre and fluid intake

Common side effects (affecting 1–10% of patients):

• •Vomiting: More likely with faster dose escalation or large meals
• •Abdominal pain or discomfort: Usually mild and intermittent
• •Dyspepsia (indigestion): Particularly after fatty or heavy meals
• •Fatigue: Some patients report tiredness, particularly in the early weeks
• •Injection site reactions: Mild redness, swelling, or itching at the injection site — usually transient

Uncommon but important side effects:

• •Gallbladder problems: Rapid weight loss increases the risk of gallstones. Symptoms include severe upper abdominal pain, particularly after meals. Seek medical attention if suspected
• •Pancreatitis: Rare but serious. Symptoms include severe, persistent abdominal pain radiating to the back. Seek emergency medical attention
• •Hypoglycaemia: More relevant for patients also taking insulin or sulfonylureas for diabetes. Less common in non-diabetic patients

Managing side effects:

• •Eat slowly and stop when you feel satisfied — do not push through fullness
• •Avoid high-fat, greasy, or very large meals (these exacerbate nausea significantly)
• •Stay hydrated — sip water throughout the day
• •Consider ginger tea or supplements for nausea
• •If constipation develops, increase fibre intake gradually and ensure adequate hydration
• •Report any side effects to your prescriber — dose adjustments can often help

When to seek urgent medical help:

• •Severe, persistent abdominal pain (especially if radiating to the back)
• •Signs of an allergic reaction (difficulty breathing, swelling of face/throat, severe rash)
• •Persistent vomiting preventing adequate fluid intake
• •Signs of dehydration (dark urine, dizziness, confusion)

As two of the most effective weight management medications available in the UK, Mounjaro (tirzepatide) and Wegovy (semaglutide 2.4mg) are frequently compared. Here is an objective overview of how they differ.

Mechanism of action:

• •Mounjaro: Dual GIP and GLP-1 receptor agonist — activates two incretin pathways simultaneously
• •Wegovy: Pure GLP-1 receptor agonist — activates only the GLP-1 pathway

Clinical efficacy (weight loss):

• •Mounjaro 15mg: Approximately 20–26% mean weight loss in clinical trials (SURMOUNT programme)
• •Wegovy 2.4mg: Approximately 15–17% mean weight loss in clinical trials (STEP programme)
• •Head-to-head data from the SURMOUNT-5 trial (comparing tirzepatide directly with semaglutide) confirmed tirzepatide's superiority for weight loss

Dosing schedule:

• •Both are once-weekly subcutaneous injections
• •Mounjaro has a 6-step escalation (2.5→5→7.5→10→12.5→15mg)
• •Wegovy has a 5-step escalation (0.25→0.5→1→1.7→2.4mg)

Side effect profile:

• •Both share similar GI side effects (nausea, diarrhoea, constipation)
• •Some analyses suggest Mounjaro may have slightly lower rates of nausea at equivalent efficacy levels, possibly due to the GIP component's moderating effect on gastric motility

UK availability and cost:

• •Both are available through NHS and private channels
• •Private costs are broadly similar (£150–£300/month depending on dose)
• •Supply chain stability has been variable for both medications — check current availability with your pharmacy

Cardiovascular data:

• •Wegovy has established cardiovascular outcome data from the SELECT trial, demonstrating a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in people with established cardiovascular disease
• •Mounjaro's cardiovascular outcome trial (SURPASS-CVOT) results are expected but not yet fully published at the time of writing. Early signals are positive

Which is right for you?

The choice between Mounjaro and Wegovy should be made in consultation with your prescriber, taking into account your specific health profile, weight loss goals, any previous medication experience, and insurance/cost considerations. Neither medication is universally "better" — they are different tools with different strengths.

This article is for educational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before starting or switching weight management medications.